Risk factor
Very high price volatility
Profitability factor
Favourable analyst view
About
Syndax Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer. Its lead product candidates are SNDX-5613, which is in phase 1/2 clinical trial targeting the binding interaction of Menin with the mixed lineage leukemia 1 protein for the treatment of MLL-rearranged (MLLr) and nucleophosmin 1 mutant acute myeloid leukemia (NPM1c AML);...
Company Valuation
Considering past and projected metrics, the stock is distinctly 'expensive' compared to its peers. In particular, the stock is 'expensive' on EV/EBITDA, overvalued on P/F
Target Price
The average target price of SNDX is 39 and suggests 92% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increase
Buy
Sell